Faeth Therapeutics, Inc. (FTH) stock

FTHNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30

$10.65−2.70 (-20.22%)

Close on Nov 12, 2026Market cap $275.20MP/E –Yield –

Faeth Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q1 FY2021	Mar 31, 2021	$3.37M	–
Q1 FY2020	Mar 31, 2020	$2.20M	–

See a number that looks wrong?